CytoSorbents Corp. (CTSO)
6.01
+0.66
(+12.34%)
USD |
NASDAQ |
Oct 22, 16:00
5.71
-0.30
(-4.99%)
After-Hours: 05:38
CytoSorbents Enterprise Value : 44.46M for Oct. 22, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 22, 2026 | 44.46M |
| October 21, 2026 | 42.38M |
| October 20, 2026 | 42.29M |
| October 19, 2026 | 41.16M |
| October 16, 2026 | 38.48M |
| October 15, 2026 | 35.19M |
| October 14, 2026 | 35.28M |
| October 13, 2026 | 36.44M |
| October 12, 2026 | 36.85M |
| October 09, 2026 | 37.48M |
| October 08, 2026 | 37.29M |
| October 07, 2026 | 37.73M |
| October 06, 2026 | 38.01M |
| October 05, 2026 | 38.03M |
| October 02, 2026 | 38.30M |
| October 01, 2026 | 38.72M |
| September 30, 2026 | 37.83M |
| September 29, 2026 | 38.14M |
| September 28, 2026 | 38.20M |
| September 25, 2026 | 39.33M |
| September 24, 2026 | 39.08M |
| September 23, 2026 | 41.00M |
| September 22, 2026 | 42.29M |
| September 21, 2026 | 42.88M |
| September 18, 2026 | 43.64M |
| Date | Value |
|---|---|
| September 17, 2026 | 43.67M |
| September 16, 2026 | 43.58M |
| September 15, 2026 | 44.61M |
| September 14, 2026 | 44.64M |
| September 11, 2026 | 45.71M |
| September 10, 2026 | 45.59M |
| September 09, 2026 | 45.46M |
| September 08, 2026 | 47.09M |
| September 04, 2026 | 47.57M |
| September 03, 2026 | 47.57M |
| September 02, 2026 | 49.69M |
| September 01, 2026 | 46.81M |
| August 31, 2026 | 47.00M |
| August 28, 2026 | 46.66M |
| August 27, 2026 | 46.96M |
| August 26, 2026 | 48.19M |
| August 25, 2026 | 47.90M |
| August 24, 2026 | 48.84M |
| August 21, 2026 | 48.82M |
| August 20, 2026 | 45.12M |
| August 19, 2026 | 47.94M |
| August 18, 2026 | 48.19M |
| August 17, 2026 | 49.28M |
| August 14, 2026 | 50.70M |
| August 13, 2026 | 48.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Abbott Laboratories | 205.04B |
| AngioDynamics, Inc. | 486.71M |
| Alphatec Holdings, Inc. | 2.243B |
| AtriCure, Inc. | 2.923B |
| Baxter International, Inc. | 19.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.417M |
| Revenue (Quarterly) | 9.633M |
| Total Expenses (Quarterly) | 14.05M |
| EPS Diluted (Quarterly) | -1.407 |
| Gross Profit Margin (Quarterly) | 73.18% |
| Profit Margin (Quarterly) | -45.85% |
| Earnings Yield | -96.55% |
| Normalized Earnings Yield | -90.14 |